T3 Technion Technology Transfer
T3 Technion Technology Transfer is the technology transfer unit of the Technion – Israel Institute of Technology in Israel. The unit operates under the auspices of the Technion Research & Development Foundation. Overview. T3 is staffed by an 11-member team whose focus is to commercialize new ideas in science and technology from Technion in Israel, by finding investors and entrepreneurs to develop commercial applications. This includes licensing intellectual property and the establishment of start-up companies. The team has been described as "the private sector's gateway to Technion innovation". As of 2011, 424 patents were granted  to Technion innovations, with 845 patents pending. T3's partners include incubators, entrepreneurs, private investors, venture capitalists and angel groups. It also conducts strategic partnerships with multinational companies such as Microsoft, IBM, Intel, Philips, Johnson & Johnson, Coca-Cola, and others. The name T3 was taken to represent the three 'Ts' in Technion Technology Transfer, and to indicate that scientific breakthrough is taken to another dimension (cubed) when developed and applied as solutions in the real world. Since 2005, the unit has been managed by Benjamin Soffer, a lawyer who has served on the board of directors of companies including Genegraft , SLP Ltd, Regentis Biomaterials, EORD, Guide-X and Slender Medical. Soffer was special advisor to Israel's Chief Scientist at the Israeli Ministry of Industry and Trade. Commercialization strategies. T3's strategy is to escort Technion technologies from the initial point of discovery, through the process of development and licensing, to the formation of ventures with industry. Commercialization strategies are tailored to the requirements of each venture, in order to enhance the market value and performance of Technion discoveries and increase their success in the global marketplace. This includes: Rasagiline is a drug to treat Parkinson's disease discovered by  Prof. Moussa B.H. Youdim of Technion and John Finberg. It was developed in collaboration with Teva Pharmaceuticals Ltd, in Israel. Having won U.S. Food and Drug Administration approval, the drug is now marketed worldwide as Azilect. Programs. Entrepreneur in residence program. The unit runs an Entrepreneur In Residence program, in which global entrepreneurs are recruited and are given the chance to license new Technion technologies. The program normally requires a minimal amount of equity and the presentation of a business plan. As part of its effort to attract entrepreneurs, the group uses its network of venture capitalists, Incubators, head-hunting  firms and service providers. Finders. The Technion liaises with global professionals from various industries, in order to spread information about Technion innovations to potential partners. Mentorship program. The Mentorship Program (based mainly on Technion alumni) T3 engages serial entrepreneurs as mentors to fledgling entrepreneurs/researchers. These mentors offer their experience, network and understanding of industry and provide insights as to the preferred commercialization route or application. The mentor is often engaged as a paid consultant supporting the commercialization efforts, Investment opportunities fund. The Technion has secured an internal US$10 million fund called the Technion Investment Opportunities Fund. The fund  invests in syndication with other investors and aims to preserve the equity stake in Technion related companies. Internal applicable research funds. One of the biggest challenges in technology transfer is the gap between early research products, and the level of evidence investors need to support further research. The Technion's internal applicable research funds are aimed at bridging this gap by taking promising projects beyond the proof of concept stage. Awards. The Technion awards researchers, inventions, developments and publications from its scientists that have a profit potential. The goal of the award is to encourage entrepreneurship in research. The researchers  are rated based on commercial applicability (such as potential market share), and technological maturity. The Technion network. The American Technion Society and global Technion societies have created an international network. Many members of Technion Societies are prominent leaders in their respective fields. T3 makes every use of this international source of expertise in the service of its on-going commercialization effort. Outsideactivities. Webinars. The Technion has initiated a webinar program aimed at presenting Technion innovation to an audience of investors, industry leaders, entrepreneurs, corporate executives, in-licensing officers and service providers. The purpose of this program is to increase visibility  and to assist in marketing and commercialization efforts. Independently, T3 maintains an active presence in the social media on LinkedIN, Facebook and Twitter. MBA – global patent course. This program is the result of a combined effort by the Dingman Center for Entrepreneurship at the University of Maryland, T3 and Technion's MBA program. Within this initiative, MBA students (an equal amount of Israeli and American students from Maryland University and Harvard University), collaborate on a business plan aimed at commercializing patents and technologies developed by Technion researchers. The course offers hands-on experience in commercialization and starting a company involving  a real-life innovation. At the end of the course, students present their business plan to a group of seasoned venture capitalist and serial entrepreneurs. Internal technology transfer seminars. The group conducts seminars and workshops to Technion faculty and graduate students dealing with different aspects of commercialization, e.g., patenting, entrepreneurship, finance, fund raising, licensing, company formation Professional conferences. The members of the team presents in national and international conferences related to commercialization, licensing, and technology transfer. These include the Israeli, European and US Biomed conferences, AUTM conferences, and Nanotechnology conferences. AMIT. The Technion is the first university outside of the  U.S. selected by Alfred E. Mann to be a part of his network of Alfred Mann Institutes (AMIs). The Alfred Mann Institute at the Technion (AMIT) was established with an endowment exceeding US$100 million. Among the patents developed by AMIT is the electronic nose to sniff out cancer, invented by Hossam Haick